Allergic Rhinitis Market Size in the US was ~USD 3,600 million in 2023 and it is further expected to increase by 2034, estimates DelveInsight

DelveInsight's "Allergic Rhinitis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Allergic Rhinitis, historical and forecasted epidemiology as well as the Allergic Rhinitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Discover Key Insights into the Allergic Rhinitis Market with DelveInsight's In-Depth Report @ Allergic Rhinitis Market Size [https://www.delveinsight.com/sample-request/allergic-rhinitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Allergic Rhinitis Market Report

* In September 2025, Advagene Biopharma Co. Ltd . announced a study to assess the safety, tolerability and efficacy of 3 doses of AD17002 in comparison to placebo. Subjects will be randomized at 3:1 ratios in each of 3 cohorts to receive AD17002 or placebo.
* In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Allergic rhinitis in the 7MM were nearly 90 million in 2023.
* The highest total diagnosed prevalent cases of Allergic rhinitis were accounted by Japan in 2023 (~26 million), which are expected to show a rise in the future.
* Among the European countries, Germany had the highest diagnosed prevalent cases of Allergic rhinitis with ~10 million cases, followed by the United Kingdom, with ~9 million in 2023. Spain had the lowest cases (~5 million cases).
* Japan had 26 million total diagnosed prevalent cases of Allergic rhinitis in 2023, accounting for approximately 30% in 7MM.
* DelveInsight's analysis revealed that in 2023, about 20% of Allergic rhinitis cases in the 7MM were classified as mild, 60% as moderate, and 20% as severe.
* The age-specific diagnosed prevalent cases of allergic rhinitis were segmented in four age groups- 0-10 years, 10-17 years, 18-59 years, and 60 and above. In 2023, in the 7MM age group 18-59 years had the highest cases of allergic rhinitis (~60 million), followed by 60 and above, 10-17 years and 0-10 years.
* In 2023, in the 7MM, the allergen-specific diagnosed prevalent cases of allergic rhinitis were highest for grass pollen, followed by tree pollen, mites, weed pollen, animal dander, and fungal spores.
* The leading Allergic Rhinitis Companies such as Regeneron, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals, Inc., Abdi Ibrahim Pharmaceuticals, Inmunotek, NeuCen BioMed, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC, Emergo Therapeutics, Inimmune, Paradigm Biopharmaceuticals, Siolta Therapeutics, Revelation Biosciences Inc., Allergy Therapeutics,Marinomed Biotech, Dobecure, Hyloris Pharmaceuticals , and others.
* Promising Allergic Rhinitis Therapies such as GSK256066, Azelastine Hydrochloride, Fluticasone Furoate Nasal Spray, Stapokibart Injection, CM310, MK0476, Loratadine, FEX60/PE10 and others.

Stay ahead in the Allergic Rhinitis Therapeutics Market with DelveInsight's Strategic Report @ Allergic Rhinitis Market Outlook [https://www.delveinsight.com/sample-request/allergic-rhinitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Allergic Rhinitis Epidemiology Segmentation in the 7MM

* Allergic Rhinitis Prevalent Cases
* Allergic Rhinitis Diagnosed Prevalent Cases
* Allergic Rhinitis Severity-Specific Diagnosed Prevalent Cases
* Allergic Rhinitis Age-specific Diagnosed Prevalent Cases
* Allergen-specific sensitivity of Diagnosed Prevalent Cases

Download the report to understand which factors are driving Allergic Rhinitis epidemiology trends @ Allergic Rhinitis Prevalence [https://www.delveinsight.com/sample-request/allergic-rhinitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Allergic Rhinitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Allergic Rhinitis market or expected to get launched during the study period. The analysis covers Allergic Rhinitis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Allergic Rhinitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Allergic Rhinitis Marketed Drugs

* RYALTRIS (Olopatadine Hydrochloride and Mometasone Furoate Monohydrate Nasal Spray): Glenmark Pharmaceuticals Inc.

RYALTRIS is a metered, fixed-dose, aqueous suspension, prescription drug product nasal spray approved by the FDA for treating symptoms associated with Seasonal Allergic Rhinitis. Each unit of Ryaltris nasal spray contains 665 mcg of olopatadine hydrochloride, a histamine-1(H1)-receptor inhibitor, and 25 mcg of mometasone furoate, a corticosteroid.

Emerging Allergic Rhinitis Drugs

* REGN5713-5714-5715: Regeneron Pharmaceuticals

REGN5713-5714-5715 is an investigational combination of three fully human monoclonal antibodies designed to treat allergic inflammatory conditions caused by the allergen Betv1, which is the main allergen responsible for birch pollen allergies. Birch allergy can trigger reactions such as allergic rhinitis and asthma. The Bet v1-specific mAbs (REGN5713, REGN5714, and REGN5715) were generated using Regeneron's VelocImmune platform. Preclinical studies demonstrated that the three mAbs bind independently and non-competitively to Bet v 1. All three together provided maximal inhibition of Bet v 1 binding to human polyclonal IgE and potently blocked basophil activation ex vivo and mast cell degranulation in vivo. The multi-antibody therapy is currently in Phase III of development.

* Grass MATA MPL: Allergy Therapeutics

Grass MATA MPL contains an extract of 13 grass pollens modified with glutaraldehyde to form allergoids that reduce the reactivity with immunoglobulin E (IgE) antibodies without a reduction in other important immunological properties, such as T-cell reactivity. The allergoid is adsorbed to microcrystalline tyrosine as a depot adjuvant system formulation. Monophosphoryl lipid-A (MPL) is included as an adjuvant to increase the immunogenic effect of the immunotherapy and to enhance the switch from an allergen-specific helper T-cell Type 2 (Th2) to helper T-cell Type 1 (Th1) like an immune response. Grass MATA MPL is being developed as a pre-seasonal SC immunotherapy product for treating allergic rhinitis and/or rhinoconjunctivitis. In November 2023, Allergy Therapeutics completed the Phase III study to evaluate the efficacy and safety of PQ grass in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass pollen.

Get In-Depth Knowledge on Allergic Rhinitis Market Trends and Forecasts with DelveInsight @ Allergic Rhinitis Treatment Market [https://www.delveinsight.com/sample-request/allergic-rhinitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Allergic rhinitis Market Outlook

The treatment goal for allergic rhinitis is to relieve symptoms. Therapeutic options to achieve this goal include avoidance measures, nasal saline irrigation, oral antihistamines, intranasal corticosteroids, combination intranasal corticosteroid/antihistamine sprays; leukotriene receptor antagonists (LTRAs), and allergen immunotherapy. The complete spectrum of pharmacologic treatments for allergic rhinitis includes FDA-approved medications and off-label treatments. For mild AR, nasal washes help remove mucus. Off-label treatments for allergic rhinitis include antihistamines, which are effective for treating occasional allergy symptoms and can be used as nasal sprays. Corticosteroid nasal sprays are the most effective treatment for allergic rhinitis and work best when used continuously but are also helpful for shorter or intermittent use. These sprays are generally safe for children and adults and come in various brands, both off-label and prescription-based. Decongestants can also help reduce nasal stuffiness.

Scope of the Allergic Rhinitis Market Report

* Study Period: 2020-2034
* Coverage: 7MM
* Allergic Rhinitis Companies- Regeneron, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals, Inc., Abdi Ibrahim Pharmaceuticals, Inmunotek, NeuCen BioMed, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC, Emergo Therapeutics, Inimmune, Paradigm Biopharmaceuticals, Siolta Therapeutics, Revelation Biosciences Inc., Allergy Therapeutics,Marinomed Biotech, Dobecure, Hyloris Pharmaceuticals , and others.
* Allergic Rhinitis Therapies- GSK256066, Azelastine Hydrochloride, Fluticasone Furoate Nasal Spray, Stapokibart Injection, CM310, MK0476, Loratadine, FEX60/PE10 and others.
* Allergic Rhinitis Therapeutic Assessment: Allergic Rhinitis current marketed and Allergic Rhinitis emerging therapies
* Allergic Rhinitis Market Dynamics: Allergic Rhinitis market drivers and Allergic Rhinitis market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Allergic Rhinitis Unmet Needs, KOL's views, Analyst's views, Allergic Rhinitis Market Access and Reimbursement

Unlock Strategic Insights with DelveInsight's Comprehensive Allergic Rhinitis Market Report @ Allergic Rhinitis Market Drivers and Barriers [https://www.delveinsight.com/sample-request/allergic-rhinitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

1. Allergic Rhinitis Market Report Introduction

2. Executive Summary for Allergic Rhinitis

3. SWOT analysis of Allergic Rhinitis

4. Allergic Rhinitis Patient Share (%) Overview at a Glance

5. Allergic Rhinitis Market Overview at a Glance

6. Allergic Rhinitis Disease Background and Overview

7. Allergic Rhinitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Allergic Rhinitis

9. Allergic Rhinitis Current Treatment and Medical Practices

10. Allergic Rhinitis Unmet Needs

11. Allergic Rhinitis Emerging Therapies

12. Allergic Rhinitis Market Outlook

13. Country-Wise Allergic Rhinitis Market Analysis (2019-2032)

14. Allergic Rhinitis Market Access and Reimbursement of Therapies

15. Allergic Rhinitis Market Drivers

16. Allergic Rhinitis Market Barriers

17. Allergic Rhinitis Appendix

18. Allergic Rhinitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=allergic-rhinitis-market-size-in-the-us-was-usd-3600-million-in-2023-and-it-is-further-expected-to-increase-by-2034-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/allergic-rhinitis-market

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.